Suprefort
Research OnlyA cytamin-class peptide supplement derived from pancreatic tissue, part of the Russian bioregulator framework. Marketed as an oral supplement for pancreatic support. Contains peptide complexes rather than defined sequences. No Western clinical validation.
Pancreatic cytamin · Pancreas peptides · A-11 pancreatic peptides
Preclinical evidence only
- Preclinical
- 83%
- Clinical
- 0%
Based on 6 cited sources
Demonstrated effect magnitude — not a recommendation or safety claim.
Research Depth 14: Suprefort itself (undefined pancreatic tissue cytamin) has zero human studies; the only adjacent in-vivo evidence is the defined-peptide analog Pancragen in old rhesus monkeys (PMID 28509500, animal = 1A 6), at high RoB with no RCT (1B 2), total human N 0 (1C 0), indirect surrogate/animal/ different-compound evidence (1D 2), and a modest pancreatic-class preclinical base (1E 4). Mechanism 28: for the defined KEDW peptide a DNA acct-sequence binding site is inferred (PMID 27909961, 2A 10) with partial downstream pancreatic-differentiation signaling (PMID 31808038, 2B 8), concentration- dependence in single model (2C 5), in-vivo mammalian for the class (2D 8) — but Suprefort is an undefined mixture, weakening target attribution. Plausibility 50: pancreatic-support claim needs ≥1 unproven link (oral tissue- peptide bioavailability, mixture→effect) (3A 12), coherent with bioregulator biology with indirect Pancragen glucose-normalization support (3B 15), same- class agent shows analogous pancreatic effect (3C 11), tightly scoped single claim (3D 12). Global Coverage 18: single Russian group (Khavinson/St. Petersburg), one country, <5 Suprefort-specific studies, no governance review. Community Experience 14: dossier reports no meaningful real-world usage or user reports; near-negligible documented use with only a thin marketed track record. Effectiveness not-established: no quantified human efficacy estimate and no meaningful community effect signal.
Mechanism of Action
Suprefort is a cytamin-class supplement containing peptide complexes derived from pancreatic tissue.
Proposed Mechanisms
- Pancreatic Support - Claimed to support pancreatic gland function
- Digestive Enzymes - Proposed effects on enzyme production
- Metabolic Function - Marketed for pancreatic health
Important Limitations
- NOT a defined peptide - contains complex mixture
- Oral peptide bioavailability is generally very low
- No Western clinical validation
- No randomized controlled trials
- NOT a treatment for diabetes or pancreatic disorders
- Not approved by any Western regulatory agency
Pancragen
CompatibleBoth target pancreatic function - Pancragen is synthetic KEDW tetrapeptide, Suprefort is tissue-derived cytamin supplement.
Epithalon
CompatibleBoth Khavinson bioregulator products with distinct tissue targets.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Suprefort
Related Peptides
225Ac-DOTA-LM3
Actinium-225-DOTA-LM3 · 225Ac-DOTA-JR11 · Alpha-PRRT +1
An alpha-emitting radiolabeled somatostatin receptor antagonist for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Unlike conventional beta-emitting Lu-177 therapies and SSTR agonists, 225Ac-DOTA-LM3 combines the higher cell-killing power of alpha particles with antagonist binding for enhanced tumor targeting. Clinical stage investigational therapy showing promise in Lu-177-refractory patients.
Bronchogen
AEDL · Ala-Glu-Asp-Leu · Bronchial tetrapeptide +1
A synthetic tetrapeptide (Ala-Glu-Asp-Leu) developed by Russian scientist Vladimir Khavinson for bronchial and respiratory tissue support. Claimed to modulate bronchial epithelium gene expression and provide respiratory protective effects. No Western clinical validation; all evidence from Russian bioregulator research.
BT5528
Bicycle Toxin Conjugate 5528 · EphA2-BTC
A first-in-class Bicycle Toxin Conjugate (BTC) targeting EphA2-expressing tumors, developed by Bicycle Therapeutics. Combines a constrained bicyclic peptide targeting moiety with the cytotoxic payload MMAE. The first-in-human Phase I (45 patients, advanced solid tumors) reported a 6.7% overall response rate and 20% disease control at the recommended Phase 2 dose; expansion ongoing.
Cardiogen
AED · Ala-Glu-Asp · Cardiac tripeptide
A synthetic tripeptide (Ala-Glu-Asp, AED) developed by Russian scientist Vladimir Khavinson and marketed as a cardiac "bioregulator." Despite that marketing, no PubMed-indexed study has examined AED in heart, cardiomyocyte, or myocardial tissue. The only published AED research is in vitro and non-cardiac — anti-aging gene-expression effects in cultured stem cells, fibroblasts, kidney and immune cells. No human or animal data and no regulatory approval anywhere.
Chelohart
Heart cytamin · Cardiac peptide supplement · A-7 heart peptides
A cytamin-class peptide supplement derived from cardiac (heart) tissue, part of the Khavinson bioregulator framework. Marketed as an oral supplement for cardiac health support. Contains peptide complexes rather than defined sequences. Very limited clinical validation, primarily Russian-language literature.
Chonluten
EDG-GI · Glu-Asp-Gly (GI) · GI tract tripeptide +1
A synthetic tripeptide (Glu-Asp-Gly) developed by Vladimir Khavinson for gastrointestinal tissue support. Shares the same amino acid sequence as Kristagen but is marketed for digestive system rather than immune function. Limited to Russian studies with no Western validation or clinical trials.